Biological Evaluation of a Novel Anti-inflammatory Treatment in Immune-mediated Inflammatory Diseases
Not Applicable
Completed
- Conditions
- Inflammation
- Interventions
- Biological: Blood sample
- Registration Number
- NCT02839278
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Brief Summary
The aim of the study is to investigate in vitro the impact of a novel anti-inflammatory treatment on costimulatory molecules expressed on monocytes.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
- Immune-mediated inflammatory disease (non-ST segment elevation myocardial infarction, Rheumatoid arthritis, Chronic obstructive pulmonary disease, Idiopathic pulmonary fibrosis, Crohn's disease, Ulcerative colitis, Cystic fibrosis, Psoriasis, Multiple sclerosis or major depressive episode)
- Patient able to understand the reason of the study
- Patient not opposed to the conservation of biological samples for scientific research
Exclusion Criteria
- Pregnant woman
- Subject without health insurance
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Immune-mediated inflammatory disease Blood sample Patients with an immune-mediated inflammatory disease. A blood sample is achieved at T0 (no follow-up).
- Primary Outcome Measures
Name Time Method Expression of costimulatory molecules CD86, CD80, CD40 and class II (HLA-DR) on monocytes 24 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University Hospital
🇫🇷Besançon, France